Codiak BioSciences Stock

codiakbio.comHealthcare / BioTech & PharmaFounded: 2015Funding to Date: $168.37MM

Codiak is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need.

Register To Buy and Sell Shares

For more details on financing and valuation for Codiak BioSciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Codiak BioSciences’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Codiak BioSciences.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Douglas E. Williams, Ph.D.
President, Chief Executive Officer & Board Member
Linda C. Bain
Chief Financial Officer
Richard Brudnick
Chief Business Officer & Head of Strategy
Andrea Difabio
Chief Legal Officer

Board Members

Theo Melas-Kyriazi
Jonathan Poole
Eric S. Lander, Ph.D.
Karen Bernstein, Ph.D.
Steven Gillis, Ph.D.
Charles L. Cooney, Ph.D.
Briggs W. Morrison, M.D.
Douglas E. Williams, Ph.D.

News Highlights

Jazz, Codiak to Partner on Exosome Therapeutics for Cancer in $1B+ Collaboration
Jazz Pharmaceuticals will use Codiak BioSciences’ engEx™ precision engineering platform to research, develop and commercialize exosome therapeutics for cancer through a collaboration that could generate more than $1 billion for Codiak,
Updated on: Apr 24, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.